L1M Drilling contractor appointed
Lightning Minerals (ASX:L1M) reports appointment of Gyro Drilling Australia for its upcoming Aircore drill program planned to commence in January 2024 targeting high priority lithium in soil anomalism up to 218ppm Li1 | ASX announcement: https://clients3.weblink.com.au/pdf/L1M/02753786.pdf #L1M #shorts
RNE Collaborating with Mitsubishi Corporation subsidiary
ReNu Energy (ASX:RNE) has announced a collaboration with a subsidiary of the Mitsubishi Corporation to conduct studies for RNE’s green hydrogen project opportunity at Portland in Victoria. ReNu Energy and DGA will initially each have a 50% participating interest in the Project | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231213/pdf/05yhrzy2zr9lfs.pdf #shorts
TTT Enters Partnerships
Titomic (ASX:TTT), a leading manufacturing technology company, announces a strategic manufacturing partnership agreement with Stärke Advanced Manufacturing Group (Stärke), a global, advanced manufacturer headquartered in South Australia https://yourir.info/resources/2daff4293b7634ea/announcements/ttt.asx/3A633039/TTT_Titomic_enters_Manufacturing_Partnership_Agreement.pdf #shorts
TNC confidently commits to restart mining at its Cloncurry Copper Project
True North Copper (ASX:TNC) announces that its Board has endorsed the Cloncurry Copper Project mining restart plan. In another important development, recent positive exploration and development outcomes across the Great Australia Mine Reserve and the Wallace North Resource has resulted in the Company’s decision to combine both projects as part of the mine | ASX […]
CRSP U.S. FDA approved first therapy utilising CRISPR
The beginning of a new era in medicine: The U.S. FDA has today approved cell-based gene therapy Casgevy, marking the first FDA-approved therapy utilising the genome editing technology CRISPR (NASDAQ:CRSP) | https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease #FDA #CRISPR #shorts
WA1 High grade central zone
WA1 Resources (ASX: WA1) announces further exploration results from drilling at the 100% owned West Arunta Project in Western Australia with assays from the central zone demonstrating continuity of the shallow high-grade blanket of niobium mineralisation https://app.sharelinktechnologies.com/announcement/asx/bcf96f0d9b1a1079082bc988d84a27df #shorts
BUB Achieves record weekly U.S. revenue of ~$770k
Bubs Australia (ASX:BUB) provided an update on the strong growth and accelerating consumer demand in the U.S. as it achieved record weekly revenue in the U.S. during November 2023 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231211/pdf/05ydpq3q5nxgbg.pdf #BUB #UnitedStates #shorts
SIG to merge with Chemist Warehouse Group
Sigma Healthcare (ASX:SIG) is to merge with CW Group Holdings (the Chemist Warehouse Group), creating a leading healthcare wholesaler, distributor and retail pharmacy franchisor. It combines SIG’s extensive and state-of-the-art distribution infrastructure with CW Group’s leading retailing know-how | ASX announcement: https://investorcentre.sigmahealthcare.com.au/static-files/d2c377b3-f487-4488-b34d-43c02330e6b7 #SIG #mergers #shorts
4DX Acquires Imbio
4DMedical (ASX:4DX) announces it has signed a binding agreement for the acquisition of Imbio, a U.S.-based medical technology company that uses artificial intelligence to turn standard-of-care CT scans into personalised medicine https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02752243-3A632933 #4DX #acquisition #shorts
CYP Phase 2 Trial approved
Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts